Flibanserin
From Wikipedia, the free encyclopedia
Flibanserin
|
|
Systematic (IUPAC) name | |
1-[2-[4-(3-trifluoromethyl phenyl) piperazin-1-yl] ethyl] benzimidazol- [1H]-2-one | |
Identifiers | |
CAS number | |
ATC code | ? |
PubChem | ? |
Chemical data | |
Formula | C20H21F3N4O |
Mol. mass | 390.40 g/mol |
Pharmacokinetic data | |
Bioavailability | ? |
Metabolism | ? |
Half life | ? |
Excretion | ? |
Therapeutic considerations | |
Pregnancy cat. |
? |
Legal status | |
Routes | ? |
Flibanserin[1] is a drug produced by Boehringer Ingelheim. It is currently being investigated as a drug for women suffering from decreased sexual desire. It is a 5-HT1A serotonin receptor agonist and 5-HT2a serotonin receptor antagonist that had initially been developed as an anti-depressant.[2]
[edit] References
- ^ Borsini F, Evans K, Jason K, Rohde F, Alexander B, Pollentier S (summer 2002). "Pharmacology of flibanserin". CNS Drug Rev. 8 (2): 117–142.
- ^ Invernizzi RW, Sacchetti G, Parini S, Acconcia S, Samanin R (Aug 2003). "Flibanserin, a potential antidepressant drug, lowers 5-HT and raises dopamine and noradrenaline in the rat prefrontal cortex dialysate: role of 5-HT(1A) receptors.". Br J Pharmacol. 139 (7): 1281–8. doi: .
[edit] External links
- Viagra for women?.
- Region-dependent effects of flibanserin and buspirone on adenylyl cyclase activity in the human brain
- Flibanserin has anxiolytic effects without locomotor side effects in the infant rat ultrasonic vocalization model of anxiety
- Effect of flibanserin (BIMT 17), fluoxetine, 8-OH-DPAT and buspirone on serotonin synthesis in rat brain